🌐 Worldwide oncology professionals network | Run by oncologists, for colleagues | All tumor types | Non-profit 🚨 We are #OncoAlert | Oncology360°
Worldwide
Joined March 2019
- Tweets127K
- Following139
- Followers42.8K
- Likes139K
Pinned Tweet
Visit Our New Website 🚨 Science Directly From People Who Presented It
👉 oncoalert360.com/events/esmo…
No noise. No ads. Just oncology, for colleagues, by colleagues.
OncoAlert is with you every day, not just at congresses. Our website brings you the science you need to stay up to date, with no fluff, no distractions and no advertising.
We are a non-profit Organization with one mandate: keeping colleagues worldwide up to date. For almost a decade, OncoAlert has been made 100% by physicians, by oncologists for oncologists. Some of the biggest names in oncology are part of this network, and they use it to bring new findings directly to you.
@cdanicas · @hoperugo · @DrChoueiri · @TiansterZhang · @matteolambe · @NiuSanford · @stolaney1 · @christine_lovly · @amerseburger · @GlopesMd · @tompowles1 · @montypal · @Icro_Meattini · @PGrivasMDPhD · @brian_rini · @CathyEngMD · @apolo_andrea · @AndreaNecchi · @DrSGraff · @BenWestphalen · @graokane · @to_be_elizabeth · @ElisaAgostinett · @nataliagandur · @UOzkerim · @DrMirallas · @DrYukselUrun · @Lucarecco · @mzugman · @HHorinouchi · @p_ciracimd · @DraMartinezLago · @DrVilmaPBarcia · @GIMedOnc · @MarioBalsaMD · @scocmem · @AmandaNizamMD · @GaiaGriguolo · @JankovicK · @Dr_Oncologista · @Erman_Akkus · @WeOncologists · @niklas_kluemper · @Markuseckstein3
OncoAlert retweeted
This is an important release in @JCO_ASCO in conjunction with #ESMO26 #DASL HiCaP trial. Identifying pts who benefit the most from intensified treatment is a work in progress. @ASCO @myESMO @ChrisSweens1 #ENZARAD @Prof_IanD et al. @OncoAlert
ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer | Journal of Clinical Oncology ascopubs.org/doi/pdf/10.1200…
OncoAlert retweeted
New in #JIPO: "Evidence for Dose Optimization of Immune Checkpoint Inhibitors", an invited commentary by Dr Sewanti Limaye and colleagues.
doi.org/10.36401/JIPO-26-X7
@SewantiLimaye
@ANaingMD
@HajjarJoud
@weoncologists
@MDerbalaMD
@mirella_nardo
@ErulEnes
@ImeneHadji1
@RegmiSunil1
@OncologyNetwork
@OncoAlert
OncoAlert retweeted
This is where complete evidence — p, fragility, robustness, plus absolute effect size — earns its keep. A p-value alone can’t tell a knife-edge interim result from a settled one. Here all four align: p<0.001; stable classification (SFQ 0.82, z = 6.5, nowhere near the significance boundary); far from no effect (SRQ 0.46, HR 0.42); and the absolute gain is clinically meaningful: +8.4 months median OS, 12-month survival 79.4% vs 53.3%. Statistical evidence is fully concordant, supporting the claim. Contrast this study with other unstable ‘significant’ trials that flip on one patient. Same p<0.05 culture, very different evidence. This study appears solid. This is great news.
OncoAlert retweeted
What #BreastCancer advances should be on your radar? 🎧
Drs. @oreganruth and @KalinskyKevin discuss treatment de-escalation, emerging therapies & more in the latest #CancerSpeak.
🎙️ cancerspeak.podbean.com/e/to…
📄 acsjournals.onlinelibrary.wi…
@OncoAlert #BCSM
OncoAlert retweeted
Check out the #ESMO26 Coverage and our NEW website👉 oncoalert360.com/events/esmo…
Visit Our New Website 🚨 Science Directly From People Who Presented It
👉 oncoalert360.com/events/esmo…
No noise. No ads. Just oncology, for colleagues, by colleagues.
OncoAlert is with you every day, not just at congresses. Our website brings you the science you need to stay up to date, with no fluff, no distractions and no advertising.
We are a non-profit Organization with one mandate: keeping colleagues worldwide up to date. For almost a decade, OncoAlert has been made 100% by physicians, by oncologists for oncologists. Some of the biggest names in oncology are part of this network, and they use it to bring new findings directly to you.
@cdanicas · @hoperugo · @DrChoueiri · @TiansterZhang · @matteolambe · @NiuSanford · @stolaney1 · @christine_lovly · @amerseburger · @GlopesMd · @tompowles1 · @montypal · @Icro_Meattini · @PGrivasMDPhD · @brian_rini · @CathyEngMD · @apolo_andrea · @AndreaNecchi · @DrSGraff · @BenWestphalen · @graokane · @to_be_elizabeth · @ElisaAgostinett · @nataliagandur · @UOzkerim · @DrMirallas · @DrYukselUrun · @Lucarecco · @mzugman · @HHorinouchi · @p_ciracimd · @DraMartinezLago · @DrVilmaPBarcia · @GIMedOnc · @MarioBalsaMD · @scocmem · @AmandaNizamMD · @GaiaGriguolo · @JankovicK · @Dr_Oncologista · @Erman_Akkus · @WeOncologists · @niklas_kluemper · @Markuseckstein3
OncoAlert retweeted
OUT TODAY!!
THE COMPLETE #ESMO26 NEWSLETTER 📰
Bringing together our top picks from the most important trials presented in Madrid, all in one email.
📩 Register to receive it: buff.ly/N5gYtAc
Curated by oncologists, for colleagues in cancer care, our mission is to make the latest oncology science accessible, relevant, and easy to digest.
We are OncoAlert 🚨 — For Colleagues, by Colleagues.
Best,
The OncoAlert Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
Join Drs Komal Jhaveri , Roberto Iacovelli and @COR2EDMedEd for some great highlights from ESMO 2026 ! 👉 Explore the coverage cor2ed.com/highlights-from-e…
Dr Jhaveri provides insights on #BreastCancer data, while Dr Iacovelli reviews developments in #ProstateCancer and #BladderCancer
@DrIacovelli @jhaveri_komal
OncoAlert retweeted
🔬 Can adding an androgen receptor inhibitor to ADT and radiotherapy improve metastasis-free survival in very high-risk localised prostate cancer? New Phase 3 interim results from DASL-HiCaP suggest a significant benefit.
📊 LBA4 – DASL-HiCaP (ANZUP1801): Darolutamide with ADT and definitive or salvage locoregional radiotherapy
cslide.ctimeetingtech.com/es…
Darolutamide added to ADT and locoregional radiotherapy significantly improved metastasis-free survival in patients with very high-risk localised or biochemically persistent/recurrent prostate cancer. At four years, metastasis-free survival was 95% versus 88% with placebo (HR 0.42; p=0.0001).
✅ These findings support treatment intensification, although longer follow-up is needed to establish whether this benefit translates into improved overall survival. #ProstateCancer
@niazi_Dr7, @Prof_IanD, @ChrisSweens1, @AlisonZhangMBBS, @seanmmcbride, @DocJarad, @DavePryorRO, @MartinStockler
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
OncoAlert retweeted
🔬 Can perioperative immunotherapy plus an antibody–drug conjugate change the treatment landscape for cisplatin-ineligible muscle-invasive bladder cancer? New Phase 3 data suggest it could.
🧬 Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer
🔗 nejm.org/doi/full/10.1056/NE…
📊 The Phase 3 trial demonstrates significant improvements in event-free survival with perioperative durvalumab plus neoadjuvant enfortumab vedotin, with or without tremelimumab, compared with radical cystectomy alone in cisplatin-ineligible or cisplatin-declining patients with muscle-invasive bladder cancer. The durvalumab–enfortumab vedotin combination also significantly improved overall survival.
✅These findings highlight a promising perioperative treatment strategy, although the substantial incidence of grade 3 or higher adverse events warrants careful consideration.
@tompowles1, @drenriquegrande, @Uro_Oncologist, @TimuinL, @HernanJCutuli, @DrRosenbergMSK
@OncoALert 🚨
OncoAlert retweeted
📌 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial
🔗 nature.com/articles/s41591-0…
📊 At 5 years:
👉 iDFS: 89.5% (Group B)
👉 iDFS: 92.4% among 86 patients achieving pCR without chemotherapy, with only one distant recurrence.
🧬 Early ctDNA clearance after two treatment cycles was associated with higher pCR rates and improved 5-year iDFS.
@OncoAlert #OncoAlertAF @NatureMedicine
🎙️ Listen to the latest oncology news from international experts at ESMO 2026!
🎧 Listen to the full podcast: bit.ly/4yQtcNu
🌍 What are the key clinical trial findings and emerging treatment strategies shaping the future of cancer care?
In this week’s VJOncology Podcast: Highlights from ESMO 2026, join leading international experts Georgina Long, Tamim Niazi, James Harding, Brian Slomovitz, and Valentina Boni as they discuss the latest advances presented at the 2026 ESMO Congress in Madrid.
🔬 Topics include:
INTerpath-001 in melanoma
DASL-HiCaP in prostate cancer
HARMONi-GI1 in biliary tract cancer
KEYNOTE-C93 in endometrial cancer
Pumitamig and emerging PD-1-targeted bispecific and bifunctional therapies in solid tumours.
@ProfGLongMIA, @niazi_Dr7, @HardingJJMD, @GynCancerMD @VJOncology
OncoAlert retweeted
🚨 #ESMO26 #Podium2Screen LITESPARK-011
@OncoAlert
A new post–PD-(L)1 option in advanced #RCC — but the story is more nuanced than PFS alone.
@DanielHengMD 🇨🇦 presents the final phase III analysis of belzutifan + lenvatinib vs cabozantinib:
📊 PFS: 14.8 vs 10.8 mo
HR 0.74
🎯 ORR: 53% vs 40%
⏳ DoR: 22.0 vs 11.9 mo
📈 OS: HR 0.85 — not statistically significant
🎯 Why this matters: belzutifan + lenvatinib delivers deeper and more durable disease control after prior immunotherapy, but without a demonstrated OS advantage.
For me, the clinically interesting question now is not simply whether this is another active post-IO regimen.
It is where it should sit in sequencing — relative to cabozantinib and other increasingly available options — and whether biology can help identify the patients most likely to benefit from HIF-2α + VEGF inhibition.
Excellent breakdown by @DanielHengMD.
@DrChoueiri @tompowles1 @brian_rini @TiansterZhang @HHammersMD @AlbigesL @montypal @apolo_andrea @crisbergerot @nataliagandur
#OncoAlert #KidneyCancer #Belzutifan #Lenvatinib #GUOncology #PrecisionOncology
OncoAlert 🚨 #ESMO26 #Podium2Screen
LITESPARK-011 final analysis in #RCC
Our @OncoAlert founding faculty @DanielHengMD 🇨🇦 presents belzutifan + lenvatinib vs cabo after anti–PD-(L)1:
➡️ PFS HR 0.74 (14.8 vs 10.8 mo)
➡️ ORR 53% vs 40%, DOR 22.0 vs 11.9 mo
➡️ OS HR 0.85, not significant
👇 #KidneyCancer #GUOnc
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
OncoAlert retweeted
Long-term follow-up from KEYNOTE-564 reinforces the durable benefit of adjuvant pembrolizumab in high-risk ccRCC. Great insights from Dr. Toni Choueiri and excellent coverage by @OncoAlert! 👏👏
OncoAlert founding faculty Dr. Toni Choueiri 🇺🇸 of Dana Farber walks us through adjuvant pembrolizumab vs placebo in high-risk ccRCC:
📊 DFS HR 0.68 | 7-yr DFS 57.2% vs 44.6%
📊 OS HR 0.70 | 7-yr OS 82.3% vs 76.6%
✅ No new safety signals
Durable benefit. Standard of care confirmed.
▶️ Watch now 👇
#kidneycancer #RCC #kidneycancer
Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3
OncoAlert retweeted
🎥 #OAOnTheGO | #ESMO26 Madrid
@OncoAlert
The most interesting part of the 6-year NATALEE update is not only that the benefit persists — it is that the gap in invasive disease-free survival continues to widen after ribociclib has stopped.
Dr. Gil Morgan @OncoAlert breaks down the new data:
📊 OS: HR 0.81
➡️ 2.1% absolute benefit at 6 years
📊 iDFS: absolute benefit now 5.3%
✅ No new safety signals
⏳ Patients are now more than 3 years off ribociclib
🎯 Why this matters: adjuvant therapy asks patients to accept treatment and toxicity today for a benefit that may only become fully visible years later.
For me, the key question is whether the widening reduction in recurrence will ultimately translate into a durable survival advantage with longer follow-up.
The OS analysis remains descriptive and the absolute difference is still modest — but this is exactly why mature follow-up matters.
🎬 Watch Dr. Gil Morgan’s clinical take in the latest #OAOnTheGO from @OncoAlert.
@matteolambe @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @kevinpunie @GaiaGriguolo @JankovicK @LoiSher
#BreastCancer #NATALEE #Ribociclib #CDK46 #AdjuvantTherapy #OncoAlert
🎥 #OAOnTheGO Series in| #ESMO26 Madrid
Dr. Gil Morgan (@OncoAlert) breaks down the 6-year NATALEE update!
In this episode of #OAOnTheGO, Dr. Gil Morgan, OncoAlert representative, breaks down the 6-year NATALEE update, simultaneously published in Annals of Oncology.
🔬 Key takeaways:
📊 Overall survival: HR 0.81, with a 2.1% absolute benefit at 6 years.
📊 Invasive disease-free survival: Absolute benefit has widened to 5.3%.
📊 No new safety signals, with patients now more than 3 years off ribociclib.
These findings strengthen the role of adjuvant ribociclib for eligible patients with high-risk, HR-positive, HER2-negative early breast cancer.
While the overall survival analysis remains descriptive and the absolute benefit is modest, the results bring an important question into focus: Can preventing more recurrences ultimately help more patients live longer?
🎬 Watch Dr. Gil Morgan's clinical take in the latest #OAOnTheGO by OncoAlert.
Pinging OncoAlert Breast Cancer Faculty
@matteolambe @aftimosp @E_de_Azambuja @DrSGraff @ErikaHamilton9 @hoperugo @stolaney1 @BianchiniGP @aftimosp @kevinpunie @ElisaAgostinett @to_be_elizabeth @GaiaGriguolo @JankovicK @raalbany @JavierCortesMD @JaniceTNBCmets @Prof_Nadia_H @LoiSher @jamecancerdoc
@Lucarecco @Dr_Oncologista @guiandri76
OncoAlert retweeted
🚨 My take on HARMONi-GI1 at #ESMO26: promising survival benefit with ivonescimab + chemo in 1L BTC, but safety and generalizability remain key questions.
Could this change our practice? 🤔
Thanks @OncoAlert for the opportunity to discuss! 💙 #OAOnTheGo
@myESMO @_SEOM @GrupoTTD
OncoAlert🚨 #OAOnTheGo | Straight from #ESMO26
Can a PD-1 × VEGF bispecific change first-line treatment for biliary tract cancer? 🤔
OncoAlert´s own Dr Vilma P. Barcia🇪🇸 (@DrVilmaPBarcia), Head of Medical Oncology at @Hospital_LaLuz (@quironsalud, GI Cancer Unit, #OneOncologyMadrid), to break down HARMONi-GI1, presented at the ESMO 2026 Presidential Symposium.
🔬 The study
Phase 3 trial of ivonescimab, a bispecific antibody targeting PD-1 and VEGF, plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer.
📊 Key results
✅ Median OS: 14.9 vs 12.1 months (HR 0.75)
✅ Median PFS: 8.4 vs 5.8 months
✅ Higher response rates
⚠️ Points to consider
🔸 More grade ≥3 adverse events with ivonescimab
🔸 The trial population was exclusively Chinese, so validation in other populations is needed
💬 Would you change your first-line practice in BTC based on these data? Tell us below 👇
▶️ Watch the full conversation with Dr Barcia.
@CathyEngMD, @BenWestphalen, @graokane, @NiuSanford,
, @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara,
OncoAlert retweeted
For years, cisplatin-ineligible MIBC meant surgery and hope.
VOLGA changes that‼️
perioperative durvalumab + 3 cycles of EV, with an OS benefit and less toxicity than control. And a lesson: the third drug didn't help.
Worth 5 minutes with @tompowles1 👇 #ESMO26
Why ‘More Drugs’ Isn’t Always Better: VOLGA Trial Redefines #BladderCancer Care
#Podium2Screen from the #ESMO26 Presidential Session
Presented by our @OncoALert 🚨faculty @tompowles1
Perioperative Durvalumab ± Tremelimumab Plus Neoadjuvant Enfortumab Vedotin in Muscle-Invasive Bladder Cancer: Results From the Phase 3 VOLGA Trial @jteoh_hk @CPRT65
🔬 Phase 3 VOLGA trial (n=695)
Evaluated perioperative durvalumab (D) ± tremelimumab (T) plus neoadjuvant enfortumab vedotin (EV) versus control (radical cystectomy [RC], followed by observation or approved adjuvant therapy) in cisplatin-ineligible muscle-invasive bladder cancer (MIBC).
Just PUBLISHED in @NEJM
nejm.org/doi/full/10.1056/NE…
Interim analysis; median event-free survival (EFS) follow-up: 22.9 months.
➡️ D + EV: EFS HR 0.51 (95% CI, 0.38–0.67); OS HR 0.58 (95% CI, 0.40–0.83)
➡️ D + T + EV: EFS HR 0.61 (95% CI, 0.47–0.80); OS did not meet statistical significance
➡️ Pathological complete response (pCR): 45% with D + EV vs 10% with control
➡️ Grade 3/4 treatment-related adverse events (TRAEs): 30% with D + EV vs 42% with control
✅ Both primary EFS endpoints were met. Perioperative durvalumab plus 3 cycles of neoadjuvant EV also significantly improved OS.
🎙️ Presenter: Thomas Powles
👥 Investigators: Alexandra Drakaki · Jeremy Teoh · Enrique Grande · Mario Fontes-Sousa · Camillo Porta · Esther Wu · Erik Goluboff · Svetlana Ho · Stephan Hois · Ashok Gupta · James Catto
@DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @niklas_kluemper @Markuseckstein3
OncoAlert retweeted
Must read newsletter by @oncoalert !
#ESMO26
OUT TODAY!!
THE COMPLETE #ESMO26 NEWSLETTER 📰
Bringing together our top picks from the most important trials presented in Madrid, all in one email.
📩 Register to receive it: buff.ly/N5gYtAc
Curated by oncologists, for colleagues in cancer care, our mission is to make the latest oncology science accessible, relevant, and easy to digest.
We are OncoAlert 🚨 — For Colleagues, by Colleagues.
Best,
The OncoAlert Network
@cdanicas @hoperugo @DrChoueiri @TiansterZhang @matteolambe @NiuSanford @stolaney1 @christine_lovly @amerseburger @GlopesMd @tompowles1 @montypal @Icro_Meattini @PGrivasMDPhD @brian_rini @CathyEngMD @apolo_andrea @AndreaNecchi @DrSGraff @BenWestphalen @graokane @to_be_elizabeth @ElisaAgostinett @nataliagandur @UOzkerim @DrMirallas @DrYukselUrun @Lucarecco @mzugman @HHorinouchi @p_ciracimd @DraMartinezLago @DrVilmaPBarcia @GIMedOnc @MarioBalsaMD @scocmem @AmandaNizamMD @GaiaGriguolo @JankovicK @Dr_Oncologista @Erman_Akkus @WeOncologists @niklas_kluemper @Markuseckstein3
OncoAlert retweeted
📢 Join us at the 44th Annual Chemotherapy Foundation Symposium (CFS®): Innovative Cancer Therapy for Tomorrow 📅 November 11–13, 2026 (NY, NY🇺🇸 )
REGISTER 👉 buff.ly/3G9pRP6
HYBRID MEETING (Online and In Person)
🚨 FREE🆓 REGISTRATION with Code: OncoAlert
For more than four decades, CFS® has been a premier educational event bringing together oncology professionals from around the world to explore the latest advances in cancer care. This 3-day conference will feature internationally renowned experts discussing practice-changing developments across solid tumors and hematologic malignancies, including targeted therapies, immunotherapies, novel biomarkers, and combination treatment strategies.
Attendees will gain valuable insights into:
🔹 Emerging biomarker-driven treatment approaches
🔹 Results from pivotal clinical trials
🔹 Personalized treatment strategies based on evolving evidence
🔹 Management of adverse events associated with novel therapies
Led by Program Co-Chairs:
• Benjamin Levy, MD
• John Mascarenhas, MD
• Tiffany Traina, MD, FASCO
Don't miss this opportunity to stay at the forefront of oncology and help shape the future of cancer care.
@KCArbourMD
@mishabeltran
@KellyLBolton
@HosseinBorghaei
@AjaiChari
@End_myeloma
@DrPinkalDesai
@FordePatrick
@MattGalsky
@YJanjigianMD
@DrHKantarjian
@montypal
@szusmani
@HelenaYu923
@gotoPER
DeLLphi-305🚨 A 0.42 hazard ratio for death in extensive-stage small-cell lung cancer. In a disease where we’ve celebrated gains of two to three months, this is a different level. 🫁
Tarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
nejm.org/doi/full/10.1056/NE…
@MP_3855, @ADesaiMD
📊 In the open-label phase 3 DeLLphi-305 trial, 563 patients with extensive-stage SCLC without progression after first-line chemoimmunotherapy were randomized to tarlatamab plus durvalumab or durvalumab alone as maintenance. The median overall survival was 21.1 versus 12.7 months (HR 0.42), and the median PFS 7.4 versus 1.9 months (HR 0.34). Grade ≥3 adverse events occurred in 46.8% versus 40.6%; cytokine release syndrome, mostly grade 1–2, affected nearly half of tarlatamab-treated patients. #LungCancer
Pinging our faculty
@christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD
@peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers
